Evaluation of tacrolimus‐related CYP3A5 genotyping in China: Results from the First External Quality Assessment Exercise

Tacrolimus is the most widely used immunosuppressant in solid organ transplant patients. The cytochrome P450 3A5 (CYP3A5) has been proved to be associated with tacrolimus dose requirement. Molecular detection for CYP3A5 genotyping is demanded for the optimization of treatments of tacrolimus.

[1]  Richard C. Friedberg,et al.  International Organization for Standardization (ISO) 15189 , 2017, Annals of laboratory medicine.

[2]  Michelle Whirl-Carrillo,et al.  Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) , 2016, Genetics in Medicine.

[3]  D. Hesselink,et al.  Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations , 2016, Expert opinion on drug metabolism & toxicology.

[4]  D. Nickerson,et al.  Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting , 2016, Clinical pharmacology and therapeutics.

[5]  R. Fulton,et al.  PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation , 2016, Pharmacogenetics and genomics.

[6]  D. Kuypers,et al.  Clinical determinants of calcineurin inhibitor disposition: a mechanistic review , 2016, Drug metabolism reviews.

[7]  William E. Evans,et al.  Pharmacogenomics in the clinic , 2015, Nature.

[8]  G. Lin,et al.  Improvements in CYP2C9 Genotyping Accuracy Are Needed: A Report of the First Proficiency Testing for Warfarin-related CYP2C9 and VKORC1 Genotyping in China , 2015, Journal of cardiovascular pharmacology.

[9]  Julia M. Barbarino,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing , 2015, Clinical pharmacology and therapeutics.

[10]  D. Hesselink,et al.  Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients , 2015, Expert opinion on drug metabolism & toxicology.

[11]  E. Dequeker,et al.  Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer. , 2014, The Journal of molecular diagnostics : JMD.

[12]  H. Tedesco-Silva,et al.  CYP3A5 Genotype, but Not CYP3A4*1b, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients , 2013, Clinical pharmacology and therapeutics.

[13]  A V Emanuel',et al.  [The practice of development and implementation of quality management systems in medical laboratories. The GOST R ISO 15189-2009 "medical laboratories. The detailed requirements to quality and competence". Particular difficulties of global nature]. , 2012, Klinicheskaia laboratornaia diagnostika.

[14]  M. Loriot,et al.  Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing , 2010, Clinical pharmacology and therapeutics.

[15]  D. Hesselink,et al.  Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome? , 2010, Clinical pharmacology and therapeutics.

[16]  C. García-Sepúlveda,et al.  Maxiprep genomic DNA extractions for molecular epidemiology studies and biorepositories , 2010, Molecular Biology Reports.

[17]  M. Gulley,et al.  Clinical laboratory reports in molecular pathology. , 2007, Archives of pathology & laboratory medicine.

[18]  A H Thomson,et al.  Cost-Effectiveness of Therapeutic Drug Monitoring: A Systematic Review , 2005, Therapeutic drug monitoring.

[19]  J. Squifflet,et al.  The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. , 2004, Pharmacogenetics.

[20]  J. Beilby,et al.  Quality assessment of interpretative commenting in clinical chemistry. , 2004, Clinical chemistry.

[21]  R. V. van Schaik,et al.  CYP3A5 variant allele frequencies in Dutch Caucasians. , 2002, Clinical chemistry.

[22]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[23]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[24]  R. Kershner,et al.  Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. , 1996, Transplantation.

[25]  Ulrich Broeckel,et al.  Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. , 2016, The Journal of molecular diagnostics : JMD.

[26]  A. Marchetti,et al.  Guideline on the requirements of external quality assessment programs in molecular pathology , 2012, Virchows Archiv.

[27]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I , 2010, Clinical pharmacokinetics.